IL161600A0 - Compounds and method for the treatment of over-active bladder - Google Patents

Compounds and method for the treatment of over-active bladder

Info

Publication number
IL161600A0
IL161600A0 IL16160002A IL16160002A IL161600A0 IL 161600 A0 IL161600 A0 IL 161600A0 IL 16160002 A IL16160002 A IL 16160002A IL 16160002 A IL16160002 A IL 16160002A IL 161600 A0 IL161600 A0 IL 161600A0
Authority
IL
Israel
Prior art keywords
compounds
sup
treatment
over
active bladder
Prior art date
Application number
IL16160002A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL161600A0 publication Critical patent/IL161600A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Pretreatment Of Seeds And Plants (AREA)
IL16160002A 2001-11-02 2002-11-01 Compounds and method for the treatment of over-active bladder IL161600A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0103795A SE0103795D0 (sv) 2001-11-02 2001-11-02 Compounds and method for the treatment of överactive bladder
PCT/SE2002/001991 WO2003037889A1 (fr) 2001-11-02 2002-11-01 Composes et methode de traitement de la vessie hyperactive

Publications (1)

Publication Number Publication Date
IL161600A0 true IL161600A0 (en) 2004-09-27

Family

ID=20285984

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16160002A IL161600A0 (en) 2001-11-02 2002-11-01 Compounds and method for the treatment of over-active bladder

Country Status (16)

Country Link
US (1) US7368461B2 (fr)
EP (1) EP1444220B1 (fr)
JP (1) JP2005511571A (fr)
KR (1) KR20040053239A (fr)
CN (1) CN1610676A (fr)
AT (1) ATE353886T1 (fr)
BR (1) BR0213832A (fr)
CA (1) CA2465429A1 (fr)
DE (1) DE60218203T2 (fr)
ES (1) ES2282491T3 (fr)
IL (1) IL161600A0 (fr)
MX (1) MXPA04004075A (fr)
NO (1) NO20042138L (fr)
SE (1) SE0103795D0 (fr)
WO (1) WO2003037889A1 (fr)
ZA (1) ZA200403206B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200508221A (en) 2003-06-13 2005-03-01 Astrazeneca Ab New azetidine compounds
DE102004001873A1 (de) * 2004-01-14 2005-09-29 Bayer Healthcare Ag Cyanopyrimidinone
WO2006121389A1 (fr) * 2005-05-10 2006-11-16 Astrazeneca Ab Utilisation d'un antagoniste du recepteur de la neurokinine-2 pour traiter ou prevenir l'hyperactivite du detrusor
AR057828A1 (es) 2005-09-29 2007-12-19 Astrazeneca Ab Compuestos derivados de azetidina, su preparacion y composicion farmaceuutica
US8106208B2 (en) 2006-05-18 2012-01-31 Albireo Ab Benzamide compounds that act as NK receptor antagonists
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基－雜環化合物
CN112915266B (zh) * 2021-02-05 2021-11-09 武汉磁济科技有限公司 一种人工膀胱铁磁复合体及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9321557D0 (en) * 1992-11-03 1993-12-08 Zeneca Ltd Carboxamide derivatives
GB9310713D0 (en) 1993-05-24 1993-07-07 Zeneca Ltd Aryl substituted heterocycles
GB9317104D0 (en) * 1993-08-17 1993-09-29 Zeneca Ltd Therapeutic heterocycles
GB9322643D0 (en) * 1993-11-03 1993-12-22 Zeneca Ltd Lactam derivatives
US6008223A (en) 1994-10-27 1999-12-28 Zeneca Limited Therapeutic compounds
GB9421709D0 (en) * 1994-10-27 1994-12-14 Zeneca Ltd Therapeutic compounds
GB9505084D0 (en) 1995-03-14 1995-05-03 Pfizer Ltd Benzamide derivative
GB9922519D0 (en) 1998-10-07 1999-11-24 Zeneca Ltd Compounds
GB9924141D0 (en) 1998-10-30 1999-12-15 Zeneca Ltd Treatment of gastric asthma
WO2000034234A1 (fr) * 1998-12-04 2000-06-15 Rimma Iliinichna Ashkinazi Aryl- et heteroarylamides d'acides carboalcoxysulfaniliques
GB9826941D0 (en) 1998-12-09 1999-02-03 Zeneca Pharmaceuticals Compounds
GB0015246D0 (en) 2000-06-22 2000-08-16 Astrazeneca Ab Method for the treatment of urinary incontinence

Also Published As

Publication number Publication date
SE0103795D0 (sv) 2001-11-02
DE60218203D1 (de) 2007-03-29
JP2005511571A (ja) 2005-04-28
NO20042138L (no) 2004-05-25
ATE353886T1 (de) 2007-03-15
KR20040053239A (ko) 2004-06-23
DE60218203T2 (de) 2008-01-03
CA2465429A1 (fr) 2003-05-08
ES2282491T3 (es) 2007-10-16
WO2003037889A8 (fr) 2004-05-06
CN1610676A (zh) 2005-04-27
WO2003037889A1 (fr) 2003-05-08
EP1444220B1 (fr) 2007-02-14
BR0213832A (pt) 2004-08-31
MXPA04004075A (es) 2004-07-23
US7368461B2 (en) 2008-05-06
EP1444220A1 (fr) 2004-08-11
ZA200403206B (en) 2005-02-22
US20050203113A1 (en) 2005-09-15

Similar Documents

Publication Publication Date Title
WO2006044362A3 (fr) Antagonistes du recepteur 1 de n-sulfonylpiperidine cannabinoide
WO2003037271A3 (fr) Composes, compositions pharmaceutiques et methodes d'utilisation
EP2289492A3 (fr) Compositions de clorhydrate de naltrexone
UA88463C2 (ru) Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции
WO2004096798A3 (fr) Derives de 2-acylamino-4-phenylthiazole, leur preparation et leur application en therapeutique
DE60112974D1 (en) Carbolinderivate
AU1816901A (en) Benzimidazole compounds having nociceptin receptor affinity
DE60216233D1 (en) Carbolinderivate
NO20012194L (no) CRF-reseptorantagonister og tilhörende fremgangsmåter
TR200102178T2 (tr) CRF reseptör antagonistleri ve bunlarla ilgili yöntemler.
WO2001039723A3 (fr) Composes triazospiro presentant une affinite pour le recepteur de la nociceptine
IL161600A0 (en) Compounds and method for the treatment of over-active bladder
CA2412596A1 (fr) Inhibiteurs de phosphodiesterase specifique de gmp cyclique
WO2000047547A3 (fr) Composes d'amines cycloalkyles et utilisation de ceux-ci
EE05241B1 (et) Distamtsiini a-halogenoakrlolderivaadi kasutamine
WO2006004613A3 (fr) Sels de guanylhydrazone, compositions a base de ceux-ci, procedes et production et d'utilisation de ceux-ci
AU2001274786A1 (en) Method for the treatment of overactive bladder
MXPA04004071A (es) Metodo para tratamiento de vejiga hiperactiva.
CA2445620A1 (fr) Composes tetracycliques utilises comme inhibiteurs de pde5-
AU2001261850A1 (en) Crf receptor antagonists and methods relating thereto
AU2001263329A1 (en) Crf receptor antagonists and methods relating thereto
AU4937499A (en) Use of succinic acid or salts thereof and method of treating insulin resistance
WO2001068066A3 (fr) Composition comprenant de la camptothecine ou un derive de la camptothecine et un agent alkylant, destinee au traitement du cancer
TW200503675A (en) Combination of phenylcarboxamides with blockers of the Ikr channel and their use for the treatment of atrial arrhythmias
EP1584333A3 (fr) Utilisation d'inhibiteurs de l'acétylcoenzime A pour traiter l'Alzheimer